Navigation Links
Inovio Pharmaceuticals to Present at Oppenheimer Investor Conference
Date:12/12/2011

ss release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and synthetic vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable synthetic vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can
'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing
2. Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
3. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
4. Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
5. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
6. Inovio Pharmaceuticals Synthetic Vaccine for Cancer Recognized as Most Promising Research at Global Vaccine Congress
7. Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines Potential to Help Ensure Nations Food Supply Safety
8. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
9. Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
10. Inovio Pharmaceuticals to Present at Investor Conferences
11. Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... that on December 24, 2014 it closed its ... Company raised approximately $2.3 million in gross proceeds ... net proceeds from the offering to fund its ...
(Date:12/24/2014)... , December 24, 2014 ... at an average rate of 8.1%. The US has ... knee and spine surgeries are the common orthopedic procedures ... have a lower penetration. Increased number of product recalls ... Non-metallic orthopedic devices have gained popularity in the industry ...
(Date:12/24/2014)... , December 24, 2014 ... on Global Disposable Syringe Industry of 178 ... online business intelligence library. The ... Syringe Industry is a professional and deep ...  For overview analysis, the report introduces Disposable ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... Reserve" May Also Affect,Alzheimer's Risk -, WASHINGTON, June ... treating risk factors for heart disease and stroke,such ... the progression,of Alzheimer's disease, according to research reported ... Prevention,of Dementia in Washington, DC. , Two new ...
... Jun 09, 2007 (MARKET WIRE via COMTEX ... owned subsidiary of Endo,Pharmaceuticals Holdings Inc. (NASDAQ: ... randomized, double-blind, placebo-controlled,clinical trial evaluating Frova (frovatriptan ... treatment in women with,difficult-to-treat menstrual migraine (MM). ...
Cached Medicine Technology:Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 2Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 3Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 4Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 5Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 6Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 7Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 2Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 3Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 4Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 5Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 6Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 7
(Date:12/26/2014)... Abilene, Texas (PRWEB) December 26, 2014 Yisrayl ... has written an open letter in light of the Ferguson, ... year history of civil unrest and explains why it has ... the reason mankind was even created. He says there is ... in detail. Yisrayl also says there is a set of ...
(Date:12/26/2014)... 26, 2014 “Many people become overwhelmed ... injury claim issues and phone calls with insurance companies,” ... article featuring their free eBook on pedestrian and ... on pedestrian and bicycle auto accident claims assures the ... capable of professionally handling their case while they focus ...
(Date:12/26/2014)... 26, 2014 DW-InductionHeating.com (DaWei Induction Heating ... researching and developing, producing and marketing of a series ... business announces their new series of induction brazing ... the company, induction brazing refers to the ... filler material and heat. The manager says that there ...
(Date:12/25/2014)... This is a professional and in-depth ... industry with a focus on the Chinese market. The ... the Sterilizers manufacturers and is a valuable source of ... the industry. This report provides a basic overview of ... In this part, the report presents the company profile, ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... 25 The HHS Office of HIV/AIDS Policy,s AIDS.gov will ... with a special focus on reducing HIV/AIDS-related stigma and promoting ... World AIDS Day will also mark the second anniversary of ... and resources. , , AIDS.gov ...
... guide treatment choices, researchers say , , TUESDAY, Nov. 25 ... genetic model for predicting the risk of recurrence in ... a team at the Duke Institute for Genome Science ... to chemotherapy and targeted therapy regimens. , The researchers ...
... available in Spanish . , A new ... the first time since the report was first issued in ... are decreasing for both men and women, driven largely by ... The report notes that, although the decreases in overall ...
... , , HARRISBURG, Pa., Nov. ... West Middlesex Area School District, the Pennsylvania Department of Health ... Middlesex Junior/Senior High School on Nov. 19 and Nov. 24. ... tetanus/diphtheria/pertussis vaccine was given to approximately 560 parents, students, and ...
... Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today that the ... Conference on Tuesday, December 2, 2008 at,noon Eastern Time. The ... through a link on the investors section of Gen-Probe,s website ... days following,the event. , ...
... with chronic obstructive pulmonary disorder must weigh risks, benefits, ... A new review of existing data confirms that some ... with the lung disease known as chronic obstructive pulmonary ... raise the risk of pneumonia in patients with COPD, ...
Cached Medicine News:Health News:HHS' AIDS.gov to Use Blogs, Virtual Worlds, and Social Networks to Deliver HIV Information for World AIDS Day 2008 2Health News:Gene Test Could Predict Colon Cancer's Return 2Health News:Annual report to the nation finds declines in cancer incidence and death rates 2Health News:Annual report to the nation finds declines in cancer incidence and death rates 3Health News:Annual report to the nation finds declines in cancer incidence and death rates 4Health News:Annual report to the nation finds declines in cancer incidence and death rates 5Health News:Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference 2Health News:Steroid Inhalers Raise Pneumonia Risk for Lung Disease Patients 2Health News:Steroid Inhalers Raise Pneumonia Risk for Lung Disease Patients 3
... a scientifically advanced multinutrient that ... and full body health. It ... including a diverse array of ... lycopene and OptiBerry and important ...
... Ocuvite® Extra vitamin and mineral supplements ... original formula plus more. Ocuvite ... and higher levels of vitamins C ... also contains other antioxidants and minerals ...
HydroEye is an exclusive formulation designed to provide dry eye relief and support the body's natural tear formation. Like all ScienceBased Health formulations, it is produced in softgel form for ma...
Expert QC data management solution...
Medicine Products: